• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Unveils Voalte Linq Device Powered by Scotty Assistant at HIMSS25 to Advance Voice-Activated Technology in Hospital Settings

    3/4/25 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    • Baxter's first voice-activated technology is designed to enable care at the speed of voice
    • Engineered to integrate with Baxter's existing connected care portfolio
    • Designed to reduce the burden on care teams, enhance IT and operational efficiency, and support safety through streamlined communication and workflow activation

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today unveiled Voalte Linq device powered by Scotty assistant, the company's first voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq, a lightweight, wearable badge, is powered by Scotty assistant, a voice-activated technology, to better enable efficient, streamlined communication between care teams, with the goal of freeing up more of their time and energy to focus on direct patient care.

    Voalte Linq powered by Scotty assistant is Baxter's latest innovation in connected care to provide health systems with an ecosystem that promotes full connectivity for care teams and their patients. With its network of connected devices, Baxter is better enabling connected hospital environments through the sharing and integration of data across devices, systems and healthcare institutions. A connected care environment can streamline care coordination, support informed decision-making and enhance the clinician and patient experience.

    Voalte Linq powered by Scotty assistant can be integrated with existing products from Baxter's care communications suite, a subset of its connected care portfolio, including Voalte Mobile and Voalte Nurse Call. Voalte Mobile is a set of mobile applications that communicates actionable patient information and alerts directly to staff members' smartphones to streamline care coordination, while Voalte Nurse Call works as a hospital call bell system that sends detailed patient notifications directly to care teams. With the addition of Voalte Linq powered by Scotty assistant, these solutions can work in tandem to help enhance communication and activate workflows across healthcare settings with speed and accuracy.

    "The launch of Voalte Linq powered by Scotty assistant marks an exciting step for Baxter's connected care evolution, with the introduction of our first voice-activated technology," said Donny Patel, president, Connected Care and Technical Services at Baxter. "As one of the first in the industry to leverage technology of this kind to drive workflow automation for hospital settings, we aim to transform how care teams communicate with one another and their patients."

    High-quality patient care requires effective, efficient, and reliable communication.1 However, many clinical teams and other healthcare staff still rely on outdated systems that often result in communication delays, such as pagers, intercoms and landlines. These antiquated devices require the disruption of at least two staff members waiting to make and receive calls, interrupting workflows and affecting patient care. 2 Furthermore, communication failures were identified as the root cause of more than 60 percent of sentinel events, according to the Joint Commission.3

    Voice-activated technology is an emerging way for care teams to address these challenges. Activated by a simple ‘Hey Scotty,' Voalte Linq aims to:

    • Reduce the burden on care teams: Clear, reliable voice-activated technology, coupled with a comfortable design, will enable care teams to communicate quickly while on the move.
    • Enhance IT and operational efficiency: Ability to integrate with other Baxter solutions will help promote automated workflows utilizing assignments and directories.
    • Support patient and staff safety: The ability to initiate Voalte Nurse Call duress workflow via voice-activated technology or speed-dial a pre-defined number with a configurable button may help support rapid response during critical moments.

    Voalte Linq powered by Scotty assistant can be used to support facility-wide communication or unit-specific communication, such as in the Operating Room, Emergency Department, and Labor and Delivery. It will be showcased at HIMSS25 in booth #4343 and is expected to have general availability in the U.S. in the second half of 2025. Learn more about Voalte Linq powered by Scotty assistant here.

    About Baxter

    Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    This release includes forward-looking statements concerning potential benefits associated with Voalte Linq powered by Scotty assistant, Voalte Mobile and Voalte Nurse Call. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

    Baxter, Voalte, Voalte Linq, and Scotty are trademarks of Baxter International Inc. or its subsidiaries.

    1 Carreon HF, Dutra D. Inpatient outcomes of a hands-free, wireless communication device implementation. Computers, Informatics, Nursing. 2020; 38(7): 323-328.

    2 Holland TM. 5 challenges impeding effective communication in healthcare. Insights. August 30, 2021. Accessed October 18, 2024. https://insights.samsung.com/2021/08/30/5-challenges-impeding-effective-communication-in-healthcare/

    3 The Joint Commission. Reducing handoff communication failures and inequities in healthcare. The Joint Commission. August 22, 2024. Accessed October 13, 2024. https://www.jointcommission.org/resources/news-and-multimedia/news/2024/08/reducing-handoff-communication-failures-and-inequities-in-healthcare/

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250304116803/en/

    Media Contact

    Alicia Freeberg, (224) 453-8920

    [email protected]

    Investor Contact

    Clare Trachtman, (224) 948-3020

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    More analyst ratings

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Soriano Maria Cecilia claimed ownership of 54,623 shares (SEC Form 3)

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    12/10/25 9:18:08 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Baxter International Inc.

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    12/3/25 4:04:17 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP,Group President,Pharma Sonig Alok covered exercise/tax liability with 3,191 shares, decreasing direct ownership by 2% to 128,219 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:02:32 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    12/4/25 4:15:43 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/25/25 4:45:37 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form FWP filed by Baxter International Inc.

    FWP - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/19/25 5:17:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

    Data shared in collaboration with The University of Texas Medical Branch, representing an analysis of more than one million intravenous (IV) infusions using Baxter's Spectrum IQ large volume infusion pumps (LVP) Evaluation of pre- and post-smart pump EMR integration data showed a reduction in patient safety alerts, time spent to program an infusion and to resolve a pump alert Findings underscore the potential role of connected infusion therapy in supporting patient safety, addressing clinician burnout and compliance Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medi

    12/11/25 8:30:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    INVESTIGATION ALERT: Berger Montague PC Investigates Baxter International Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: BAX)

    PHILADELPHIA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Baxter International Inc. ("Baxter" or the "Company") (NYSE:BAX) about an investigation into Baxter's Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter's marketing and sale of its Novum Large Volume Pump ("Novum LVP"). Shareholders of Baxter may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) 875-3015, or CLICK HERE. Berger Montague's investigation is focused on whether Baxter's Bo

    12/4/25 11:12:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amended by the Company's press release dated Nov. 19, 2025 (as it may be further amended or supplemented from time to time, the "Offer to Purchase"). The tender offers comprise Baxter's offer to purchase for cash (a) any and all of its 2.600% senior unsecured notes due 2026 (the "2026 Notes") (the "Any and All Tender Offer") and (b) a portion of its 1.9

    12/4/25 7:51:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care